OncoMed

Last updated
OncoMed Pharmaceuticals, Inc.
TypePrivate (2004-13)
Public (2013-19)
Nasdaq: OMED
Industry Pharmaceutical
Founded University of Michigan
Founders
  • Michael Clarke
  • Max Wicha
DefunctApril 23, 2019 (2019-04-23)
FateAcquired by Mereo BioPharma
Headquarters
Redwood City, California
,
United States
Key people
  • Paul Hastings (CEO)
  • John Lewicki (R&D chief)
  • Chuck Alaimo (Operations director)
Revenue US$24,700,000 (2012)
Total assets US$207,600,000 [1]  (2016)
Number of employees
  • 83 (2013)
  • 47 (2007)
Footnotes /references
[2] [3] [4] [5]

OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. [2] The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. [2] [4] As of 2013, the company had 83 employees. [3] OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". [3] The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. [4] OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. [3] [4] In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.

Contents

History

Oncomed was founded in 2004. [6]

In 2007, Oncomed consolidated its operations located in Mountain View and Palo Alto, California onto the single headquarters campus at Seaport Centre in Redwood City. [2] One of the buildings on the new campus was the former home of NeXT. [2]

In 2012, OncoMed sponsored the USAN nonproprietary name vantictumab for a human IgG2 anti-Frizzled antibody, an anti-cancer therapeutic. [7] In the same year, the company sponsored the USAN name demcizumab for a human IgG2 anti-DLL4 antibody, also an anti-cancer therapeutic. [8]

In 2014, OncoMed entered into an anti-cancer stem cell therapeutic development agreement with Celgene encompassing demcizumab and five other biologics from OncoMed's pipeline. [9] [10]

As of 2013, co-founder Max Wicha was the director of the University of Michigan Comprehensive Cancer Center and remained a consultant to OncoMed, while co-founder Michael Clarke had taken up a position at Stanford University. [4]

Competitors

In 2013, OncoMed had at least two direct competitors, both public American companies: Stemline Therapeutics and Verastem. [3] By 2014, the list of firms pursuing therapies targeting cancer stem cells had grown to include Boston Biomedical (a subsidiary of Dainippon Sumitomo Pharma), GlaxoSmithKline, Astellas Pharma, Sanofi (the American subsidiary) and Pfizer; however, Stemline and Verastem remain the only two competitors solely focused on cancer stem cells. [9] One analyst holds that OncoMed is the best positioned of the three companies focused on the cancer stem cell area. [9]

Pipeline

Clinical pipeline, Oct 2014 [9]
NameTargetIDClinical Phase
demcizumab DLL4OMP-21M18II
tarextumab Notch 2/3OMP-59R5 [11] II
vantictumab Fzd7OMP-18R5 [5] Ib
ipafricept Fzd8-fcOMP-54F28 [12] Ib
brontictuzumab Notch1OMP-52M51I
unnamedDLL4/VEGFOMP-305B83I
unnamedRSPO3OMP-131R10I

As of January 2017, Oncomed had seven clinical-stage drugs in development and four discovery-stage investigations; no OncoMed therapies have made it to market yet. [9] Two candidate drugs being co-developed with Bayer, ipafricept and vantictumab, showed in mid-2014 indications of "causing mild-to-moderate bone-related side effects" among Phase I clinical trial participants, an observation which led the company to halt enrollment and dosing in the trials, and which contributed to a sharp decline in share price. [9] [12] [13]

Demcizumab, OMP-305B83, and OMP-131R10 are being developed in collaboration with Celgene. Tarextumab and brontictuzumab are being developed in collaboration with GlaxoSmithKline Vantictumab and ipafricept are being developed in collaboration with Bayer. [14]

Corporate governance

In 2013, OncoMed's chief executive officer (CEO) was Paul Hastings, [3] who took the post in 2006. [15] As of 2007, the company's head of R&D was John Lewicki, and the director of operations was Chuck Alaimo. [2] While serving as OncoMed's CEO, Hastings was also a member of the board of directors for the California Healthcare Institute and the Bay Area Biosciences Association, as well as chairing the board of the Biotechnology Industry Organization. [15]

Related Research Articles

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

Lucatumumab is a human monoclonal antibody against CD40 development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody of IgG1/κ which is being investigated for the treatment of ovarian cancer.

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.

Girentuximab is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.

Demcizumab is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.

Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.

Vantictumab is a human IgG2 monoclonal antibody designed for the treatment of cancer.

Varlilumab is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.

Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.

Rosmantuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Cofetuzumab pelidotin is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019.

References

  1. ↑ "Archived copy". Archived from the original on 2017-01-06. Retrieved 2017-01-05.{{cite web}}: CS1 maint: archived copy as title (link)
  2. 1 2 3 4 5 6 Leuty, Ron (28 Oct 2007). "The NeXT big thing: OncoMed finds a home". San Francisco Business Times .
  3. 1 2 3 4 5 6 Timmerman, Luke (18 Jun 2013). "OncoMed Pharmaceuticals Soars in IPO Debut". Xconomy . United States.
  4. 1 2 3 4 5 "U-M start-up OncoMed has initial public offering" (Press release). University of Michigan Health System. 22 Jul 2013.
  5. 1 2 Leuty, Ron (5 Jul 2013). "OncoMed targets 4 million shares in IPO". San Francisco Business Times .
  6. ↑ Leuty, Ron (11 May 2012). "OncoMed files for $115 million IPO". San Francisco Business Times. Retrieved 2020-04-21.
  7. ↑ "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.(registration required)
  8. ↑ "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. N12/07. Retrieved 1 Dec 2014.(registration required)
  9. 1 2 3 4 5 6 De, Kanak Kanti (14 Oct 2014). "Is It Time To Consider OncoMed Pharmaceuticals Again?". Seeking Alpha .
  10. ↑ Staff (January 1, 2014). "OncoMed, Celgene in $3.3B+ Cancer Stem Cell Collaboration". Industry Watch. Gen. Eng. Biotechnol. News . p. 8.
  11. ↑ "OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 (Anti-Notch2/3) in Small Cell Lung Cancer (SCLC) and Amends Phase1b/2 Pancreatic Cancer Trial" (PDF) (Press release). OncoMed. 14 May 2013.
  12. 1 2 Grover, Natalie (13 Jun 2014). "OncoMed halts enrollment in trials of two cancer drugs". Reuters .
  13. ↑ Calia, Michael (13 Jun 2014). "FDA Imposes Partial Hold on OncoMed Early-Stage Cancer-Drug Trial". The Wall Street Journal .
  14. ↑ "Home | Mereo BioPharma".
  15. 1 2 "Paul J. Hastings". Leadership. California Healthcare Institute. Archived from the original on 2 October 2011.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.